2007•International Journal of Internal MedicineRequires access
New achievement of sildenafil therapy for pulmonary hypertension
Yin Kai-shen
Open publisher page 0 citations
Abstract
The following review discusses the achievement of sildenafil therapy for pulmonary hypertension. Sildenafil is a phosphodiestersase type 5 inhibitors which through inhibition of the breakdown of cGMP to enhance nitric oxide-dependent, cGMP-mediated pulmonary vasodilation. The use of sildenafil, alone or combined with prostacyclin or endothelin-receptor antagonist, has been showed that improvement in acute pulmonary hemodynamic and functional status.